nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolazoline—HRH2—Monoamine GPCRs—DRD4—conduct disorder	0.0442	0.0514	CbGpPWpGaD
Tolazoline—Pargyline—MAOA—conduct disorder	0.0435	0.31	CrCbGaD
Tolazoline—HRH2—Amine ligand-binding receptors—DRD4—conduct disorder	0.0371	0.0432	CbGpPWpGaD
Tolazoline—HRH2—Monoamine GPCRs—HTR2A—conduct disorder	0.0288	0.0335	CbGpPWpGaD
Tolazoline—HRH2—G alpha (s) signalling events—CGA—conduct disorder	0.0274	0.0318	CbGpPWpGaD
Tolazoline—ADRA2B—Monoamine GPCRs—DRD4—conduct disorder	0.026	0.0302	CbGpPWpGaD
Tolazoline—ADRA2C—Monoamine GPCRs—DRD4—conduct disorder	0.0243	0.0282	CbGpPWpGaD
Tolazoline—HRH2—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0242	0.0282	CbGpPWpGaD
Tolazoline—Phentermine—MAOA—conduct disorder	0.0235	0.167	CrCbGaD
Tolazoline—ADRA2B—Amine ligand-binding receptors—DRD4—conduct disorder	0.0218	0.0254	CbGpPWpGaD
Tolazoline—HRH1—Monoamine GPCRs—DRD4—conduct disorder	0.0216	0.0252	CbGpPWpGaD
Tolazoline—ADRA1A—Monoamine GPCRs—DRD4—conduct disorder	0.0212	0.0247	CbGpPWpGaD
Tolazoline—ADRA2C—Amine ligand-binding receptors—DRD4—conduct disorder	0.0204	0.0237	CbGpPWpGaD
Tolazoline—ADRA2A—Monoamine GPCRs—DRD4—conduct disorder	0.0197	0.0229	CbGpPWpGaD
Tolazoline—Phenelzine—MAOA—conduct disorder	0.0192	0.136	CrCbGaD
Tolazoline—HRH1—Amine ligand-binding receptors—DRD4—conduct disorder	0.0182	0.0211	CbGpPWpGaD
Tolazoline—ADRA1A—Amine ligand-binding receptors—DRD4—conduct disorder	0.0178	0.0207	CbGpPWpGaD
Tolazoline—ADRA2B—Monoamine GPCRs—HTR2A—conduct disorder	0.0169	0.0197	CbGpPWpGaD
Tolazoline—Methamphetamine—MAOA—conduct disorder	0.0168	0.119	CrCbGaD
Tolazoline—ADRA2A—Amine ligand-binding receptors—DRD4—conduct disorder	0.0166	0.0193	CbGpPWpGaD
Tolazoline—ADRA2C—Monoamine GPCRs—HTR2A—conduct disorder	0.0158	0.0184	CbGpPWpGaD
Tolazoline—Phentermine—SLC6A4—conduct disorder	0.0152	0.108	CrCbGaD
Tolazoline—ADRA2B—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0142	0.0166	CbGpPWpGaD
Tolazoline—HRH1—Monoamine GPCRs—HTR2A—conduct disorder	0.0141	0.0164	CbGpPWpGaD
Tolazoline—ADRA1A—Monoamine GPCRs—HTR2A—conduct disorder	0.0138	0.0161	CbGpPWpGaD
Tolazoline—ADRA2C—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0133	0.0155	CbGpPWpGaD
Tolazoline—HRH2—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.013	0.0152	CbGpPWpGaD
Tolazoline—ADRA2A—Monoamine GPCRs—HTR2A—conduct disorder	0.0129	0.015	CbGpPWpGaD
Tolazoline—HRH1—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0119	0.0138	CbGpPWpGaD
Tolazoline—Amphetamine—SLC6A4—conduct disorder	0.0117	0.0829	CrCbGaD
Tolazoline—ADRA1A—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0116	0.0135	CbGpPWpGaD
Tolazoline—ADRA2A—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0108	0.0126	CbGpPWpGaD
Tolazoline—Methamphetamine—SLC6A4—conduct disorder	0.0108	0.0768	CrCbGaD
Tolazoline—HRH2—GPCR ligand binding—CGA—conduct disorder	0.00993	0.0116	CbGpPWpGaD
Tolazoline—HRH2—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00852	0.00992	CbGpPWpGaD
Tolazoline—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00767	0.00892	CbGpPWpGaD
Tolazoline—HRH2—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.0073	0.0085	CbGpPWpGaD
Tolazoline—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00716	0.00834	CbGpPWpGaD
Tolazoline—HRH1—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00638	0.00743	CbGpPWpGaD
Tolazoline—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00626	0.00729	CbGpPWpGaD
Tolazoline—ADRA2B—GPCR ligand binding—CGA—conduct disorder	0.00584	0.0068	CbGpPWpGaD
Tolazoline—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00582	0.00677	CbGpPWpGaD
Tolazoline—HRH2—GPCR downstream signaling—CGA—conduct disorder	0.00561	0.00653	CbGpPWpGaD
Tolazoline—HRH2—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00556	0.00647	CbGpPWpGaD
Tolazoline—HRH2—GPCR ligand binding—DRD4—conduct disorder	0.00556	0.00647	CbGpPWpGaD
Tolazoline—ADRA2C—GPCR ligand binding—CGA—conduct disorder	0.00546	0.00635	CbGpPWpGaD
Tolazoline—ADRA2B—G alpha (i) signalling events—DRD4—conduct disorder	0.0054	0.00629	CbGpPWpGaD
Tolazoline—HRH2—Signaling by GPCR—CGA—conduct disorder	0.0051	0.00593	CbGpPWpGaD
Tolazoline—ADRA2C—G alpha (i) signalling events—DRD4—conduct disorder	0.00505	0.00587	CbGpPWpGaD
Tolazoline—HRH1—IL-4 Signaling Pathway—EP300—conduct disorder	0.00504	0.00586	CbGpPWpGaD
Tolazoline—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00501	0.00583	CbGpPWpGaD
Tolazoline—HRH1—GPCR ligand binding—CGA—conduct disorder	0.00486	0.00565	CbGpPWpGaD
Tolazoline—ADRA1A—GPCR ligand binding—CGA—conduct disorder	0.00477	0.00555	CbGpPWpGaD
Tolazoline—HRH2—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00476	0.00554	CbGpPWpGaD
Tolazoline—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00468	0.00545	CbGpPWpGaD
Tolazoline—ADRA2A—GPCR ligand binding—CGA—conduct disorder	0.00443	0.00516	CbGpPWpGaD
Tolazoline—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00429	0.005	CbGpPWpGaD
Tolazoline—HRH1—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00417	0.00485	CbGpPWpGaD
Tolazoline—ADRA2A—G alpha (i) signalling events—DRD4—conduct disorder	0.0041	0.00477	CbGpPWpGaD
Tolazoline—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00409	0.00476	CbGpPWpGaD
Tolazoline—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00401	0.00467	CbGpPWpGaD
Tolazoline—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.0038	0.00443	CbGpPWpGaD
Tolazoline—HRH2—GPCR ligand binding—HTR2A—conduct disorder	0.00363	0.00422	CbGpPWpGaD
Tolazoline—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00357	0.00416	CbGpPWpGaD
Tolazoline—HRH1—G alpha (q) signalling events—HTR2A—conduct disorder	0.00352	0.0041	CbGpPWpGaD
Tolazoline—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00351	0.00408	CbGpPWpGaD
Tolazoline—ADRA1A—G alpha (q) signalling events—HTR2A—conduct disorder	0.00345	0.00402	CbGpPWpGaD
Tolazoline—ADRA2B—GPCR downstream signaling—CGA—conduct disorder	0.0033	0.00384	CbGpPWpGaD
Tolazoline—ADRA2B—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00327	0.00381	CbGpPWpGaD
Tolazoline—ADRA2B—GPCR ligand binding—DRD4—conduct disorder	0.00327	0.00381	CbGpPWpGaD
Tolazoline—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00326	0.00379	CbGpPWpGaD
Tolazoline—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.00315	0.00366	CbGpPWpGaD
Tolazoline—HRH2—GPCR downstream signaling—DRD4—conduct disorder	0.00314	0.00366	CbGpPWpGaD
Tolazoline—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.00309	0.0036	CbGpPWpGaD
Tolazoline—ADRA2C—GPCR downstream signaling—CGA—conduct disorder	0.00308	0.00359	CbGpPWpGaD
Tolazoline—ADRA2C—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00306	0.00355	CbGpPWpGaD
Tolazoline—ADRA2C—GPCR ligand binding—DRD4—conduct disorder	0.00305	0.00355	CbGpPWpGaD
Tolazoline—HRH2—Signaling Pathways—CGA—conduct disorder	0.00301	0.0035	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling by GPCR—CGA—conduct disorder	0.003	0.00349	CbGpPWpGaD
Tolazoline—HRH2—Signaling by GPCR—DRD4—conduct disorder	0.00285	0.00332	CbGpPWpGaD
Tolazoline—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.0028	0.00326	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling by GPCR—CGA—conduct disorder	0.0028	0.00326	CbGpPWpGaD
Tolazoline—HRH1—GPCR downstream signaling—CGA—conduct disorder	0.00275	0.0032	CbGpPWpGaD
Tolazoline—HRH1—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00272	0.00317	CbGpPWpGaD
Tolazoline—HRH1—GPCR ligand binding—DRD4—conduct disorder	0.00272	0.00317	CbGpPWpGaD
Tolazoline—ADRA1A—GPCR downstream signaling—CGA—conduct disorder	0.00269	0.00314	CbGpPWpGaD
Tolazoline—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00267	0.00311	CbGpPWpGaD
Tolazoline—ADRA1A—GPCR ligand binding—DRD4—conduct disorder	0.00267	0.00311	CbGpPWpGaD
Tolazoline—ADRA2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00262	0.00305	CbGpPWpGaD
Tolazoline—ADRA2A—GPCR downstream signaling—CGA—conduct disorder	0.0025	0.00291	CbGpPWpGaD
Tolazoline—HRH1—Signaling by GPCR—CGA—conduct disorder	0.00249	0.0029	CbGpPWpGaD
Tolazoline—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00248	0.00289	CbGpPWpGaD
Tolazoline—ADRA2A—GPCR ligand binding—DRD4—conduct disorder	0.00248	0.00289	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling by GPCR—CGA—conduct disorder	0.00245	0.00285	CbGpPWpGaD
Tolazoline—HRH2—Signaling Pathways—WASF1—conduct disorder	0.00241	0.00281	CbGpPWpGaD
Tolazoline—HRH1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00233	0.00271	CbGpPWpGaD
Tolazoline—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00229	0.00266	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling by GPCR—CGA—conduct disorder	0.00227	0.00265	CbGpPWpGaD
Tolazoline—ADRA2B—GPCR ligand binding—HTR2A—conduct disorder	0.00213	0.00248	CbGpPWpGaD
Tolazoline—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00213	0.00247	CbGpPWpGaD
Tolazoline—HRH2—GPCR downstream signaling—HTR2A—conduct disorder	0.00205	0.00239	CbGpPWpGaD
Tolazoline—ADRA2C—GPCR ligand binding—HTR2A—conduct disorder	0.00199	0.00232	CbGpPWpGaD
Tolazoline—ADRA2C—Metabolism—CGA—conduct disorder	0.00198	0.0023	CbGpPWpGaD
Tolazoline—HRH2—Signaling by GPCR—HTR2A—conduct disorder	0.00186	0.00217	CbGpPWpGaD
Tolazoline—ADRA2B—GPCR downstream signaling—DRD4—conduct disorder	0.00185	0.00215	CbGpPWpGaD
Tolazoline—HRH1—GPCR ligand binding—HTR2A—conduct disorder	0.00178	0.00207	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—CGA—conduct disorder	0.00177	0.00206	CbGpPWpGaD
Tolazoline—ADRA1A—GPCR ligand binding—HTR2A—conduct disorder	0.00174	0.00203	CbGpPWpGaD
Tolazoline—ADRA2C—GPCR downstream signaling—DRD4—conduct disorder	0.00173	0.00201	CbGpPWpGaD
Tolazoline—HRH2—Signaling Pathways—DRD4—conduct disorder	0.00169	0.00196	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling by GPCR—DRD4—conduct disorder	0.00168	0.00195	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—CGA—conduct disorder	0.00165	0.00192	CbGpPWpGaD
Tolazoline—ADRA2A—GPCR ligand binding—HTR2A—conduct disorder	0.00162	0.00188	CbGpPWpGaD
Tolazoline—ADRA2A—Metabolism—CGA—conduct disorder	0.00161	0.00187	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling by GPCR—DRD4—conduct disorder	0.00157	0.00182	CbGpPWpGaD
Tolazoline—HRH1—GPCR downstream signaling—DRD4—conduct disorder	0.00154	0.00179	CbGpPWpGaD
Tolazoline—ADRA1A—GPCR downstream signaling—DRD4—conduct disorder	0.00151	0.00176	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—CGA—conduct disorder	0.00147	0.00171	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—CGA—conduct disorder	0.00145	0.00168	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—WASF1—conduct disorder	0.00142	0.00165	CbGpPWpGaD
Tolazoline—ADRA2A—GPCR downstream signaling—DRD4—conduct disorder	0.0014	0.00163	CbGpPWpGaD
Tolazoline—HRH1—Signaling by GPCR—DRD4—conduct disorder	0.0014	0.00163	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling by GPCR—DRD4—conduct disorder	0.00137	0.00159	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—CGA—conduct disorder	0.00134	0.00156	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—WASF1—conduct disorder	0.00133	0.00154	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling by GPCR—DRD4—conduct disorder	0.00127	0.00148	CbGpPWpGaD
Tolazoline—ADRA2B—GPCR downstream signaling—HTR2A—conduct disorder	0.00121	0.0014	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—WASF1—conduct disorder	0.00118	0.00137	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—WASF1—conduct disorder	0.00116	0.00135	CbGpPWpGaD
Tolazoline—ADRA2C—GPCR downstream signaling—HTR2A—conduct disorder	0.00113	0.00131	CbGpPWpGaD
Tolazoline—HRH2—Signaling Pathways—HTR2A—conduct disorder	0.0011	0.00128	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling by GPCR—HTR2A—conduct disorder	0.0011	0.00127	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—WASF1—conduct disorder	0.00108	0.00125	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling by GPCR—HTR2A—conduct disorder	0.00102	0.00119	CbGpPWpGaD
Tolazoline—ADRA2B—Hemostasis—EP300—conduct disorder	0.00101	0.00118	CbGpPWpGaD
Tolazoline—HRH1—GPCR downstream signaling—HTR2A—conduct disorder	0.001	0.00117	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—DRD4—conduct disorder	0.000991	0.00115	CbGpPWpGaD
Tolazoline—ADRA1A—GPCR downstream signaling—HTR2A—conduct disorder	0.000985	0.00115	CbGpPWpGaD
Tolazoline—ADRA2C—Hemostasis—EP300—conduct disorder	0.000944	0.0011	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—DRD4—conduct disorder	0.000926	0.00108	CbGpPWpGaD
Tolazoline—ADRA2A—GPCR downstream signaling—HTR2A—conduct disorder	0.000915	0.00106	CbGpPWpGaD
Tolazoline—HRH1—Signaling by GPCR—HTR2A—conduct disorder	0.000911	0.00106	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling by GPCR—HTR2A—conduct disorder	0.000894	0.00104	CbGpPWpGaD
Tolazoline—ADRA2C—Metabolism—COMT—conduct disorder	0.000893	0.00104	CbGpPWpGaD
Tolazoline—ADRA2C—Metabolism—MAOA—conduct disorder	0.000886	0.00103	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling by GPCR—HTR2A—conduct disorder	0.000831	0.000967	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—DRD4—conduct disorder	0.000825	0.00096	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—DRD4—conduct disorder	0.00081	0.000942	CbGpPWpGaD
Tolazoline—ADRA2A—Hemostasis—EP300—conduct disorder	0.000767	0.000892	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—DRD4—conduct disorder	0.000752	0.000875	CbGpPWpGaD
Tolazoline—ADRA2A—Metabolism—COMT—conduct disorder	0.000725	0.000844	CbGpPWpGaD
Tolazoline—ADRA2A—Metabolism—MAOA—conduct disorder	0.00072	0.000838	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—HTR2A—conduct disorder	0.000647	0.000753	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—HTR2A—conduct disorder	0.000604	0.000703	CbGpPWpGaD
Tolazoline—HRH2—Signaling Pathways—EP300—conduct disorder	0.000583	0.000678	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—HTR2A—conduct disorder	0.000538	0.000626	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—HTR2A—conduct disorder	0.000528	0.000615	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—HTR2A—conduct disorder	0.000491	0.000571	CbGpPWpGaD
Tolazoline—ADRA2C—Metabolism—EP300—conduct disorder	0.000383	0.000445	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—EP300—conduct disorder	0.000343	0.000399	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—EP300—conduct disorder	0.00032	0.000372	CbGpPWpGaD
Tolazoline—ADRA2A—Metabolism—EP300—conduct disorder	0.000311	0.000362	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—EP300—conduct disorder	0.000285	0.000332	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—EP300—conduct disorder	0.00028	0.000326	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—EP300—conduct disorder	0.00026	0.000303	CbGpPWpGaD
